HIV-1 and Brain Interaction on Smoking Comorbidity
Status: | Not yet recruiting |
---|---|
Conditions: | Smoking Cessation |
Therapuetic Areas: | Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 18 - 60 |
Updated: | 3/6/2019 |
Start Date: | December 1, 2019 |
End Date: | October 30, 2025 |
Contact: | Dawn Detamore |
Email: | ddetamor@mprc.umaryland.edu |
Phone: | 4104026820 |
People living with HIV-1 have high rates of cigarette smoking, which may be related to
nicotinic interaction with HIV-1 infection and brain function levels. The proposed project
aims to understand these pathways using translational brain imaging and HIV-1 reactivation
studies. The study proposes a targeted nicotine-brain investigation of the nicotinic effects
in HIV-1 infection from cellular to brain circuitry levels.
nicotinic interaction with HIV-1 infection and brain function levels. The proposed project
aims to understand these pathways using translational brain imaging and HIV-1 reactivation
studies. The study proposes a targeted nicotine-brain investigation of the nicotinic effects
in HIV-1 infection from cellular to brain circuitry levels.
Smoking remains the leading cause of preventable morbidity and mortality in the United
States. The alarmingly high smoking rates and unsatisfactory performance of standard smoking
cessation efforts in people living with HIV/AIDS (PLWH) interfere with the overall progress
in the treatment of HIV-1 infection. Our understanding of nicotine addiction mechanisms in
PLWH, and how they are related to and interact with HIV-1 neuropathology, is limited and thus
hindering the development of more effective, targeted treatments. The study will directly
address neurological complication of this HIV-associated comorbidity at the brain circuitry
level using state-of-the-art imaging tools and methods.
States. The alarmingly high smoking rates and unsatisfactory performance of standard smoking
cessation efforts in people living with HIV/AIDS (PLWH) interfere with the overall progress
in the treatment of HIV-1 infection. Our understanding of nicotine addiction mechanisms in
PLWH, and how they are related to and interact with HIV-1 neuropathology, is limited and thus
hindering the development of more effective, targeted treatments. The study will directly
address neurological complication of this HIV-associated comorbidity at the brain circuitry
level using state-of-the-art imaging tools and methods.
Inclusion Criteria:
1. Subjects between ages 18-60 in good health
2. Ability to give written informed consent
3. For people living with HIV: should be diagnosed with HIV two years or more and on ART
two years or more
4. For people living with HIV: should have achieved virologic suppression (defined as
viral loads of ≤ 200 copies/ml), and without current signs of reactivation
Exclusion Criteria:
1. Inability to sign informed consent
2. Unable to undergo MRI scanning due to metallic devices or objects (cardiac pacemaker
or neurostimulator, some artificial joints, metal pins, surgical clips or other
implanted metal parts) or claustrophobic to the scanner
3. Any major medical illnesses to include, but not limited to, uncontrolled high blood
pressure or high blood sugar, cardiovascular disease, asthma, peripheral vascular
diseases, coagulopathies, history of superficial or deep vein thrombosis as per
medical history
4. Current substance-induced psychiatric disorders
5. Significant alcohol or other drug use, other than nicotine dependence or marijuana use
6. Gross structural abnormalities and/or have a history of syncope
7. Positive urine pregnancy tests
8. Any neurological illnesses to include, but not limited to, seizure disorders, multiple
sclerosis, movement disorders, or history of head trauma, CVA, CNS tumor,
9. For people living with HIV: having AIDS or non-AIDS-defining cancer or active CNS and
other opportunistic disease
10. For people living with HIV: on active treatment of hepatitis C virus (HCV)
We found this trial at
1
site
655 West Baltimore Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
(410) 706-7410
Phone: 410-402-6820
University of Maryland School of Medicine Established in 1807, The School of Medicine is the...
Click here to add this to my saved trials